Stephanie Asher

Stephanie Asher

Auto-generated profile, based on publicly available information

Stephanie Asher

Penn Medicine, Department of Medicine Division of Translational Medicine and Human Genetics Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Biological Psychiatry
Verified
Journal Article
Closed access
BJBrett V. Johnson
Brett V. Johnson
RKRaman Kumar
Raman Kumar
SOSabrina Oishi
Sabrina Oishi
SASuzy Alexander
Suzy Alexander
MKMaria Kasherman
Maria Kasherman
LJLachlan Jolly
Lachlan Jolly

31 July 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SAStephanie B. Asher
Stephanie B. Asher
RCRensa Chen
Rensa Chen
SKStaci Kallish
Staci Kallish

25 August 2023 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
GHGlenda Hoffecker
Glenda Hoffecker
MCMari Cayabyab
Mari Cayabyab
LVLisa A. Varughese
Lisa A. Varughese
SAStephanie Byers Asher
Stephanie Byers Asher
ABArchna Bajaj
Archna Bajaj
STSony Tuteja
Sony Tuteja

4 March 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
HCHaley M. Crane
Haley M. Crane
SAStephanie Asher
Stephanie Asher
LCLaura Conway
Laura Conway
TDTheodore G. Drivas
Theodore G. Drivas
SKStaci Kallish
Staci Kallish
RBCK1‐related disease is a rare, multisystemic disorder for which our current understanding of the natural history is limited. A number of individuals initially carried clinical diagnoses of glycogen storage disease IV (GSD IV), but were later found to harbor RBCK1 pathogenic variants, demonstrating challenges of correctly diagnosing RBCK1‐related disease. This study carried out a phenotypic comparison between RBCK1‐related disease and GSD IV to identify features that clinically differentiate these diagnoses. Literature review and retrospective chart review identified 25 individuals with RBCK1‐related disease and 36 with the neuromuscular subtype of GSD IV. Clinical features were evaluated to assess for statistically significant differences between the conditions. At a system level, any cardiac, autoinflammation, immunodeficiency, growth, or dermatologic involvement were suggestive of RBCK1, whereas any respiratory involvement suggested GSD IV. Several features warrant further exploration as predictors of RBCK1, such as generalized weakness, heart transplant, and recurrent infections, among others. Distinguishing RBCK1‐related disease will facilitate correct diagnoses and pave the way for accurately identifying affected individuals, as well as for developing management recommendations, treatment, and an enhanced understanding of the natural history. This knowledge may also inform which individuals thought to have GSD IV should undergo reevaluation for RBCK1.